University of Washington

Boehringer Ingelheim International Gmbh

Eric T Larson

Dustin James Maly

Wesley C Van Voorhis

Kayode K Ojo

Ethan Merritt

Wilhelmus G J Hol

Todd Bosanac

Michael Jason Burke

Matt Aaron Tschantz

Wang Mao

Fariba Soleymanzadeh

Bryan Patrick McKibben

Joerg Bentzien

Yue Shen

Ryan Michael Fryer

Samu Taulu

Wilhelmus Gj Hol

Wilhelmus GJ Hol

Embodiments disclosed herein directed to systems, apparatuses, and methods for the suppression of artifacts in non-invasive electromagnetic recordings. A data set, such as an electroencephalography (EEG) or magnetoencephalography (MEG) data set may be recorded by a number of sensors. The data set may include contributions from a signal of interest and from artifacts. The contribution of artifacts may be suppressed by splitting the data set into projected data and residual data based on a spatial model of the signal of interest. The projected data may contain contributions from the signal of interest and artifacts, while the residual data may primarily contain contributions from artifacts. The projected and residual data may be compared to remove or reduce the contribution of artifacts from the projected data.

Apparatuses, systems, and methods for suppression of artifacts in non-invasive electromagnetic recordings

Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite() and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites() and() are described. In particular, the present disclosure is directed to compositions and methods for inhibiting eithercalcium dependent protein kinases (TgCDPKs) orandcalcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, 

Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases

The present disclosure is directed to compositions and methods for inhibiting either() calcium dependent protein kinases (TgCDPKs) or() and() calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the Formula (I), wherein the variables X, Y, Z, R, and Rare defined herein.

Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases

Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite() and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites() and() are described. In particular, the present disclosure is directed to compositions and methods for inhibiting eithercalcium dependent protein kinases (TgCDPKs) orandcalcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R, and Rare defined herein.

The present disclosure is directed to compositions and methods for inhibiting either() calcium dependent protein kinases (TgCDPKs) or() and() calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-&#x3b1;]pyrazine inhibitors, of the Formula (I), wherein the variables X, Y, Z, R, and Rare defined herein.

The present invention encompasses compounds of the formula (I) wherein the groups R, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Heteroaromatic compounds as BTK inhibitors

Growing community of inventors

Seattle, WA, United States of America

Eric T Larson